Interferons are proteins that are part of your natural defenses. They tell your immune system that germs or cancer cells are in your body. And they trigger killer immune cells to fight those invaders.

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs). Pegylated interferons are a meaningful therapeutic option for the treatment of ...

PITTSBORO, NC -- Jul 26, 2007 -- Biolex Therapeutics today announced successful initial results from the SELECT-1 Phase 2a clinical trial of Locteron(TM), the first controlled-release interferon alfa ...

ZymoGenetics has struck a deal with pharmaceutical giant Bristol-Myers Squibb that could bring the company $1 billion or more in payments if its product to treat hepatitis C reaches certain scientific ...

PISCATAWAY, N.J.--(BUSINESS WIRE)-- PBL InterferonSource—the world’s leading source of interferon and related products, services, information and expertise—announced today that its founder and chief ...

Biolex Therapeutics, Inc. announced that the results from its United States Phase 2a clinical trial (the "PLUS" trial) of Locteron® will be presented today at the 44th Annual Meeting of the European ...

Octoplus will provide manufacturing and process development services and stands to earn $138 million in milestones. Biolex Therapeutics is paying OctoPlus $11 million for its 50% share of commercial ...

We collected sales and product data for a number of biotechnology-derived therapeutic protein products, including proteins for therapeutic use (enzymes, cytokines and other proteins), growth factors, ...

The total worldwide market for MS disease-modifying therapies is expected to grow at an 8.1% compound annual growth rate (CAGR) from 2010 through 2015, with sales reaching nearly $16.7 billion by the ...